NCT06559436View on ClinicalTrials.gov

Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke

NARecruitingINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2026

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Intravenous thrombolysis

Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,

OTHER

Standard medical management

Standard medical management

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER